PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
31895562-0	2020	Discovery of a Novel, Highly Potent, and Selective Thieno[3,2-d]pyrimidinone-Based Cdc7 Inhibitor with a Quinuclidine Moiety (TAK-931) as an Orally Active Investigational Antitumor Agent.	Simurosertib	126-133	cell division cycle 7 (S. cerevisiae)	Mus musculus	83-87
31131319-0	2019	Molecular mechanism and potential target indication of TAK-931, a novel CDC7-selective inhibitor.	Simurosertib	55-62	cell division cycle 7	Homo sapiens	72-76
31131319-3	2019	We have developed an oral CDC7-selective inhibitor, TAK-931, as a candidate clinical anticancer drug.	Simurosertib	52-59	cell division cycle 7	Homo sapiens	26-30
34020950-2	2021	We developed a highly specific CDC7 inhibitor, TAK-931, as a clinical cancer therapeutic agent.	Simurosertib	47-54	cell division cycle 7	Homo sapiens	31-35